Bultmann
Andreas Bultmann, Planegg DE
Patent application number | Description | Published |
---|---|---|
20090130021 | Methods, products and uses involving platelets and/or the vasculature - The present disclosure relates to agents which interfere with the binding of GPVI to various components. Agents which interfere with GPVI interaction with one or both of fibronectin and vitronectin or sequences thereof are also disclosed. Methods of treating disorders or diseases which involve pathological, dysfunctional or non-pathological interaction of GPVI with fibronectin and/or vitronectin are included in the present disclosure. The invention also relates to uses of agents for the prevention or treatment of disorders arising from blood platelet adhesion and aggregation. | 05-21-2009 |
20100003244 | AGENTS WHICH BIND TO EPITOPES OF GLYCOPROTEIN VI - The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders. | 01-07-2010 |
20130130315 | FUSION PROTEIN - An isolated nucleic acid molecule selected from the group consisting of: vi. a nucleic acid molecule comprising a nucleotide sequence which is at least 85% identical to the nucleotide sequence of SEQ ID NO:1 or a complement thereof; vii. a nucleic acid molecule comprising a fragment of at least 1500 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof; viii. a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least 85% identical to SEQ ID NO:2; ix. a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 500 contiguous amino acids of SEQ ID NO: 2; and x. a nucleic acid molecule encoding a polypeptide containing a humanized immunoglobulin or parts of an immunoglobulin having binding specificity for CD133 a nucleic acid molecule which encodes a variant of a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising the entire SEQ ID NO: 1, or complement thereof under conditions of incubation at 45° C. in 6.0×SSC followed by washing in 0.2×SSC/0.1% SDS at 65° C. | 05-23-2013 |
20140243506 | ANTAGONISTS OF IL17C FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder. | 08-28-2014 |
Hermann Bultmann, Madison, WI US
Patent application number | Description | Published |
---|---|---|
20090253624 | Pharmacologically active antiviral peptides and methods of use - This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections. | 10-08-2009 |
20120157376 | PHARMACOLOGICALLY ACTIVE ANTIVIRAL PEPTIDES AND METHODS OF THEIR USE - This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections. | 06-21-2012 |
Martin Bultmann, Oftersheim DE
Patent application number | Description | Published |
---|---|---|
20100021540 | Tablets and Preparation Thereof - The present invention features processes of making tablets having reduced internal fractures. In one aspect, the processes comprise the steps of (1) compressing a pre-tabletting material in a die to form a tablet, where an internal surface of the die is lubricated with at least one lubricant and the pre-tabletting material comprises at least one therapeutic agent and at least one pharmaceutically acceptable polymer; and (2) ejecting said tablet from said die. In another aspect, the processes employ a granular or powdery pre-tabletting material which comprises at least one therapeutic agent and at least one pharmaceutically acceptable polymer, wherein 90% of the particles in the pre-tabletting material are smaller than 400 μm. | 01-28-2010 |
20130203791 | Tablets and Preparation Thereof - The present invention features processes of making tablets having reduced internal fractures. In one aspect, the processes comprise the steps of (1) compressing a pre-tabletting material in a die to form a tablet, where an internal surface of the die is lubricated with at least one lubricant, and the pre-tabletting material comprises at least one therapeutic agent and at least one pharmaceutically acceptable polymer; and (2) ejecting said tablet from said die. In another aspect, the processes employ a granular or powdery pre-tabletting material which comprises at least one therapeutic agent and at least one pharmaceutically acceptable polymer, wherein 90% of the particles in the pre-tabletting material are smaller than 400 μm. | 08-08-2013 |
Sebastian Bultmann, Olching DE
Patent application number | Description | Published |
---|---|---|
20140178873 | NOVEL METHODS FOR DETECTING HYDROXYMETHYLCYTOSINE - The present invention provides a method of detecting a hydroxymethyl (hm) cytosine (C) in a nucleic acid molecule preparation; comprising: (a) providing a single-stranded (ss) nucleic acid molecule; (b) synthesizing at least one copy of at least a portion of the complementary strand of said ss nucleic acid molecule thereby generating a double-stranded (ds) nucleic acid molecule, wherein said synthesis is carried out in the presence of hydroxymethylcytosine or analog thereof (e.g., protected hydroxyl group); and (c) reacting the product obtained in (b) (all or purified) with an endonuclease being capable of cleaving said ds nucleic acid molecule, wherein cleavage by said endonuclease requires a recognition site that contains hmC on opposite strands; and (d) analyzing the product obtained in step (c). | 06-26-2014 |